Article Sidebar
Views pdf: 88
LDL CHOLESTEROL CONTROL IN PATIENT WITH NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS
Main Article Content
Abstract
Introduction: Type 2 diabetes mellitus (T2DM) is a significant cardiovascular risk factor. Besides controlling blood glucose levels, managing other risk factors, including dyslipidemia with LDL cholesterol as a representative index, is essential to prevent the development and progression of cardiovascular complications. Objective: This study was conducted to determine the rate of LDL cholesterol control in newly diagnosed T2DM patients. Methods: A descriptive cross-sectional study was conducted on T2DM patients diagnosed within the last 6 months at the Endocrinology Clinic and Family Medicine Clinic of Ho Chi Minh City University Medical Center. Results: The study included 275 newly diagnosed T2DM patients. Cardiovascular risk stratification revealed that 3.6% of patients were at moderate risk, 53.1% at high risk and 43.3% at very high risk. Correspondingly, the overall rate of LDL cholesterol control was 37.8%. The rates of LDL cholesterol control for moderate, high and very high cardiovascular risk groups were 30.0%, 36.9% and 39.0%, respectively. Conclusion: The rate of LDL cholesterol control in newly diagnosed T2DM patients needs to be improved.
Article Details
Keywords
Newly diagnosed type 2 diabetes, LDL cholesterol control
References
2. Biswas T, Tran N, Thi My Hanh H, et al. Type 2 diabetes and hypertension in Vietnam: a systematic review and meta-analysis of studies between 2000 and 2020. BMJ Open. 2022 Aug 8;12(8):e052725.
3. Moon MK, Noh J, Rhee EJ, et al. Cardiovascular Outcomes according to Comorbidities and Low-Density Lipoprotein Cholesterol in Korean People with Type 2 Diabetes Mellitus. Diabetes Metab J. 2023 Jan;47(1):45-58. doi: 10.4093/dmj.2021.0344.
4. Ramírez-Morros A, Franch-Nadal J, Real J, et al. Clinical characteristics and degree of cardiovascular risk factor control in patients with newly-diagnosed type 2 diabetes in Catalonia. Front Endocrinol (Lausanne). 2024 Feb 8;15:1339879. doi: 10.3389/fendo.2024.1339879.
5. Bộ Y tế. Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2 (Ban hành kèm theo Quyết định số 5481/QĐ-BYT ngày 30 tháng 12 năm 2020). https://daithaoduong.kcb.vn/huong-dan-chan-doan-va-dieu-tri-dai-thao-duong-tip-2
6. Van Minh H, Van Huy T, Long DPP. Highlights of the 2022 Vietnamese Society of Hypertension guidelines for the diagnosis and treatment of arterial hypertension: The collaboration of the Vietnamese Society of Hypertension (VSH) task force with the contribution of the Vietnam National Heart Association (VNHA): The collaboration of the Vietnamese Society of Hypertension (VSH) task force with the contribution of the Vietnam National Heart Association (VNHA). J Clin Hypertens (Greenwich). 2022 Sep;24(9):1121-1138. doi: 10.1111/jch.14580.
7. Nguyen S, Nguyen D, Dang V, et al. (2024). Assessing LDL Cholesterol Management and Statin Use in Diabetic Patients: Disparities and Outcomes in a Vietnamese Tertiary Hospital Setting. BMRAT, 11(4), 6297-6304. https://doi. org/10.15419/bmrat.v11i4.876.
8. ElSayed NA, Aleppo G, Aroda VR, et al, on behalf of the American Diabetes Association. Summary of Revisions: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S5-S9. doi: 10.2337/dc23-Srev.
9. Hong SJ, Lee YJ, Lee SJ, et al; LODESTAR Investigators. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023 Apr 4;329 (13): 1078-1087. doi: 10.1001/jama. 2023.2487.
10. Tomlinson B, Chan P, Liu ZM. Statin Intolerance-An Asian Perspective. J Atheroscler Thromb. 2020 May 1;27(5):485-488. doi: 10.5551/jat.50435.